Results 261 to 270 of about 20,100 (304)

Eculizumab☆

2010
In deep review on eculizumab pharmacology and ...
CATALDI, MAURO, A. Cavaccini
openaire   +2 more sources

A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience

The Annals of Pharmacotherapy, 2023
Objective: To review the efficacy and safety of eculizumab for prevention and treatment of antibody-mediated rejection (AMR) in lung transplant recipients (LTRs).
Hanna L Kleiboeker, A. Prom, K. Paplaczyk, C. Myers   +3 more
semanticscholar   +1 more source

Eculizumab for treatment of asthma

Expert Opinion on Biological Therapy, 2012
Asthma is an inflammatory disease, which can be exacerbated by stimuli such as viral infections and exposure to allergens. Asthma continues to be a profound public health problem due to asthma exacerbation in a low proportion of patients in need of more effective medications.The C5 complement pathway has been proposed as a new target for the treatment ...
Gail M. Gauvreau, Steven G. Smith, Gordon Clark, Brittany Watson   +3 more
openaire   +2 more sources

Eculizumab in pregnancy: a narrative overview

Journal of Nephrology, 2018
Pregnancy can be a dangerous trigger for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), or hemolysis, elevated liver enzymes and low platelet (HELLP) syndrome. Due to the possibility of several serious complications, pregnancy is somewhat discouraged in the presence of the above diseases.
Sarno L., Tufano A., Maruotti G. M., Martinelli P., Balletta M. M., Russo D.   +5 more
openaire   +4 more sources

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria

American journal of hematology/oncology
Crovalimab, a novel C5 inhibitor, allows for low‐volume, every‐4‐ week, subcutaneous self‐administration. COMMODORE 1 (NCT04432584) is a phase 3, global, randomized trial evaluating crovalimab versus eculizumab in C5 inhibitor‐experienced patients with ...
Phillip Scheinberg, D. Clé, Jin Seok Kim, E. Nur, Mustafa N. Yenerel, Wilma Barcellini, Debora Bonito, V. Giai, Marek Hus, YooJin Lee, Cristina Barrenetxea Lekue, J. Panse, Yasutaka Ueda, Simon Buatois, Brittany Gentile, A. Kiialainen, Himika Patel, S. Sreckovic, Marianne Uguen, John Edwards, Zsolt Nagy, Austin G Kulasekararaj   +21 more
semanticscholar   +1 more source

Eculizumab

American Journal of Health-System Pharmacy, 2008
The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of eculizumab are reviewed.Eculizumab, a recombinant, humanized, monoclonal, immunoglobulin G antibody produced from murine myeloma cells, is the first agent to be approved for labeling by the Food and Drug ...
openaire   +2 more sources

Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications

American journal of hematology/oncology, 2022
A total of 2%–10% of patients with vascular liver disease (VLD) have paroxysmal nocturnal hemoglobinuria (PNH). Eculizumab reduces complement‐mediated haemolytic activity in PNH.
A. Plessier, M. Esposito-farese, A. Baiges, A. Shukla, J. Garcia Pagan, E. de Raucourt, I. Ollivier-Hourmand, J. Cervoni, V. de Lédinghen, Z. Tazi, J. Nousbaum, R. Bun, C. Bureau, C. Silvain, O. Tournilhac, Mathieu Gerfaud-Valentin, F. Durand, O. Goria, L. Téllez, A. Albillos, S. Gioia, O. Riggio, A. de Gottardi, Audrey Payancé, P. Rautou, L. Terriou, A. Charbonnier, L. Elkrief, R. Peffault de La Tour, D. Valla, N. Gault, F. Sicre de Fontbrune   +31 more
semanticscholar   +1 more source

Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

New England Journal of Medicine, 2006
To the Editor: The study of eculizumab by Hillmen et al. (Sept. 21 issue)1 showed stabilization of hemoglobin levels and a reduction in transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria (PNH). However, there were more patients with a history of aplastic anemia in the placebo group than in the eculizumab group (27% vs.
Maninder Pabla, Jaswinder Singh, Ashok K. Malani   +2 more
openaire   +3 more sources

Eculizumab in Paroxysmal Nocturnal Haemoglobinuria

Drugs, 2008
Eculizumab is a monoclonal antibody that binds with high affinity to the complement protein C5, preventing terminal complement-mediated intravascular haemolysis in patients with paroxysmal nocturnal haemoglobinuria (PNH). In three well designed clinical trials in patients with PNH, eculizumab blocked serum haemolytic activity and decreased transfusion ...
Lisa Charneski, Priti N. Patel
openaire   +2 more sources

Clinical Effects of Eculizumab in PNH: Poor Responders to Eculizumab

2017
Eculizumab is a humanized monoclonal antibody that targets the terminal complement protein C5 and inhibits terminal complement-mediated hemolysis associated with paroxysmal nocturnal hemoglobinuria (PNH). Seventeen Japanese patients and one native Argentinian patient were identified as having a poor response to eculizumab.
Taroh Kinoshita, Junichi Nishimura, Yuzuru Kanakura   +2 more
openaire   +2 more sources